Search
Search
Invitrogen
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promotions']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.viewpromo']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promocode']}}: {{promo.promoCode}} {{promo.promoTitle}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}
FIGURE: 1 / 1
Repaglinide is a rapid-acting insulin secretagogue used in the management of type 2 diabetes mellitus, primarily targeting postprandial glucose excursions by stimulating early-phase insulin release. Structurally, it is a carbamoylbenzoic acid derivative and belongs to the meglitinide class of drugs. Repaglinide is characterized by its short duration of action, which makes it suitable for controlling blood sugar levels around meal times. It is metabolized primarily in the liver, resulting in limited oral bioavailability due to significant first-pass hepatic metabolism. Efforts to enhance its bioavailability have led to the development of novel delivery systems, such as nanostructured lipid carriers for transdermal application. Repaglinide is often used in combination with other antidiabetic agents like metformin to optimize glycemic control. Synonyms for repaglinide include GlucoNorm, NovoNorm, Prandin, Surepost, and RG.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
If an Invitrogen™ antibody doesn't perform as described on our website or datasheet,we'll replace the product at no cost to you, or provide you with a credit for a future purchase.*
Learn more
Get expert recommendations for common problems or connect directly with an on staff expert for technical assistance related to applications, equipment and general product use.
Contact tech support